Open AccessComparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
Author(s) -
Willemse Eline A. J.,
Tijms Betty M.,
Berckel Bart N. M.,
Le Bastard Nathalie,
Flier Wiesje M.,
Scheltens Philip,
Teunissen Charlotte E.
Publication year - 2021
Publication title -
alzheimer's and dementia: diagnosis, assessment and disease monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.497
H-Index - 37
ISSN - 2352-8729
DOI - 10.1002/dad2.12182
Subject(s) - concordance , biomarker , medicine , dementia , amyloid (mycology) , cerebrospinal fluid , pathology , disease , oncology , chemistry , biochemistry
We evaluated for two novel automated biomarker assays how cerebrospinal fluid (CSF) amyloid beta (Aβ) 1– 42 ‐ratios improved the concordance with amyloid positron emission tomography (PET) positivity compared to Aβ 1– 42 alone. Methods We selected 288 individuals from the Amsterdam Dementia Cohort across the Alzheimer's disease clinical spectrum when they had both CSF and amyloid PET visual read available, regardless of diagnosis. CSF Aβ 1– 42 , phosphorylated tau (p‐tau), and total tau (t‐tau) were measured with Elecsys and Lumipulse assays, and Aβ 1–40 with Lumipulse. CSF cut‐points were defined using receiver operating characteristic (ROC) for amyloid PET positivity. Results For both Elecsys and Lumipulse the p‐tau/Aβ 1– 42 , Aβ 1– 42 /Aβ 1– 40 , and t‐tau/Aβ 1– 42 ratios showed similarly good concordance with amyloid PET (Elecsys: 93,90,90%; Lumipulse: 94,92,90%) and were higher than Aβ 1– 42 alone (Elecsys 85%; Lumipulse 84%). Discussion Biomarker ratios p‐tau/Aβ 1– 42 , Aβ 1– 42 /Aβ 1– 40 , t‐tau/Aβ 1– 42 on two automated platforms show similar optimal concordance with amyloid PET in a memory clinic cohort.